Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Manganese-primed Immunochemotherapy in Advanced Ovarian Cancer
NCT07822646Phase 3Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of manganese chloride in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Progression-Free Survival at 12 months. Started Oct 2026; status: recruiting.
02
Drugs
manganese chloride
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07822646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822646.